Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 7/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | GPR183 | P32249 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119674 | 0.87 | GRM5 (0.47) | HRH3GRM5ENPP2ATXN2ALDH1A1 | |
| SCHEMBL5128519 | 0.86 | SCN9A (0.47) | HRH3GRM5KCNH2ENPP2ATXN2 | |
| SCHEMBL5119714 | 0.85 | GRM5 (0.45) | HRH3GRM5ENPP2ATXN2ALDH1A1 | |
| SCHEMBL5129433 | 0.85 | GRM5 (0.49) | GRM5ENPP2ATXN2KDM4EALDH1A1 | |
| SCHEMBL5120355 | 0.83 | GRM5 (0.53) | GRM5ENPP2ATXN2KDM4EMAPK1 | |
| SCHEMBL5129000 | 0.83 | GRM5 (0.52) | GRM5ENPP2ATXN2KDM4EALDH1A1 | |
| SCHEMBL5122295 | 0.83 | GRM5 (0.43) | HRH3GRM5ENPP2ATXN2 | |
| SCHEMBL5129292 | 0.82 | KDM4E (0.51) | GRM5ENPP2ATXN2KDM4EALDH1A1 | |
| SCHEMBL5118130 | 0.82 | GRM5 (0.48) | GRM5ENPP2ATXN2KDM4EALDH1A1 | |
| SCHEMBL5130180 | 0.82 | MEN1 (0.47) | GRM5ENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | HRH3 330/4885GRM5 1/4885MAOA 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.